Open Source Drug Discovery

Jaqueline Hargis | Skepchick | March 8, 2012

Drug discovery is challenging, lengthy, and extraordinarily expensive. All companies focus on making money and drug companies are no different. They spend their research and development budgets focusing on diseases that affect the affluent world population. As a consequence diseases such as malaria and tuberculosis that are abundant in sub-Saharan Africa and India are left unstudied by industry. Despite the omission by drug companies, other efforts are underway to aid in drug discovery for these diseases...

A few years ago, Samir Brahmachari launched the Open Source Drug Discovery (OSDD) network. The initiative began in 2008 and set out to combat India’s leading cause of death, TB. The initial $12 million of seed money was provided by the Indian government and that has led to 5500 participants in 130 countries. So has this global network of researchers provided any results? Their first goal was to sequence the TB genome and the task was accomplished in a mere four months by 500 volunteers. Since then they utilized this information and have determined two viable drug candidates that are currently being tested. Following the principles of OSDD, the data from their clinical trials are open for all to see. It is too soon to tell if the drugs will be successful, but if so they will be on the market as generic drugs...